Antimullerian Hormone as an Indicator for Ovarian Response

• Conditions: Infertility, Female

• Registration Number: NCT03291860
• Lead Sponsor: Ain Shams Maternity Hospital

Brief Summary

Anti Mullerian hormone (AMH) is gaining place as ovarian marker, chiefly in infertility assistance.

Investigators explored its correlation with oocytes retrieval after long GnRH agonist protocol for stimulation, in younger and older infertile population. Methods: This prospective analysis compiled data of 66 females, receiving ICSI treatment from April 2016 to October 2017. Serum FSH, LH, Estadiol, AMH and antral follicle count were assessed. Outcomes were measured as good (5 to 19 oocytes) and bad responders.

Detailed Description

Not available

Study Timeline

• Status Verified: 2017-09
• Study First Submitted: 2017-09-18
• Study First Submitted QC: 2017-09-22
• Last Update Submitted: 2017-09-22
• Study First Posted: 2017-09-25
• Last Update Posted: 2017-09-25
• Study Start: 2017-11-10
• Primary Completion: 2018-09-10
• Study Completion: 2018-10-10

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 66

Inclusion Criteria

1. Age:20-40 years old

2. BMI:20-40kg/m

3. Normal baseline hormonal profile (on the 2nd day of the cycle)

   • FSH: 2.5-10.2mlU/ml
   • LH:1.9-12.5mlU/ml
   • Estradiol (E2): <50pg/ml

4. No Endometriosis by laparoscopy

5. No prior ovarian surgery; overectomy, ovariectomy or oophrectomy

6. Female subjects who have at least 1 wash-out cycle (defined as greater than or equal to 30 days since the last dose of clomiphene citrate or gonadotrophin treatment) since the last ART cycle and/or clomiphene citrate or gonadotrophin treatment prior to starting gonadotrophin releasing hormone (GnRH) agonist therapy

Exclusion Criteria

• 1. Age: <20 or >40 years old 2. BMI: <20 or >40kg/m 3. Female subjects with any contraindication for pregnancy. 4. Female subjects with history of tumors of the hypothalamus & pituitary gland.

  2. Female subjects with history of ovarian, uterine or mammary cancer. 6. Female subjects with history of hypersensitivity to the active substance of the medications used for ovarian stimulation.

  3. Abnormal baseline hormonal profile 8. Endometriosis by laparoscopy 9. Previous ovarian surgery; overectomy, ovariectomy or oophrectomy 10. Female subjects with abnormal gynecological bleeding of unknown etiology

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Difference between AMH levels between good and poor responders in young patients receiving long GnRH agonist protocol for ICSI.	1 month (1 cycle)	Measurement of AMH level in patients undergoing controlled ovarian stimulation prior to ICSI using long GnRH agonist protocol. Level will be compared between good and poor responders.